Hypoactive sexual desire disorder is the most common cause of sexual dysfunction in women. According to a national survey, approximately a third of all women experience low sexual desire. The etiology of the disorder is often multifactorial. Research in treatment options for hypoactive sexual desire disorder is limited. In this article, treatment options including sex therapy, hormone therapy (estrogen, testosterone, dehydroepiandrosterone, tibolone), non-hormonal medical therapies (buproprion, buspirone, phosphodiesterase-5 inhibitors, amantadine and apomorphine) and herbal therapies (Avlimil®, Arginmax®, Zestra®, yohimbine and Ginkgo biloba) are reviewed.
Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
2.
LaumannEOPaikARosenRC: Sexual dysfunction in the United States: prevalence and predictors. JAMA281, 537–544 (1999).
3.
Landmark study on the prevalence of sexual dysfunction and the determinants and health consequences of these disorders in various age and social groups in the USA.
4.
BassonR: Definitions of women's sexual dysfunction reconsidered: advocating expansion and revision. J. Psychosom. Obstet. Gynaecol. 24, 221–229 (2003).
5.
Another landmark paper from an international panel of experts in this field that discusses the evidence for gender differences in sexual response and presents a revised definition of subtypes of female sexual dysfunction based on the new model of the female sexual-response cycle.
6.
SegravesRTCroftHKavoussiR: Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J. Sex Marital Ther. 27(3), 303–316 (2001).
7.
PlautSMGraziottinAHeatonJP: Fast Facts: Sexual Dysfunction. Health Press Limited, Oxford, UK99–117 (2004).
8.
Excellent pocket handbook discussing female and male sexual function and dysfunction and treatment options.
9.
HurlbertDF: A comparative study using orgasm consistency training in the treatment of women reporting hypoactive sexual desire. J. Sex Marital Ther. 19(1), 41–55 (1993).
10.
FinchS: Sexual aversion disorder treated with behavioural desensitization. Can. J. Psychiatry46(6), 563–564 (2001).
11.
AlexanderJLKotzKDennersteinLKutnerSJWallenKNotelovitzM: The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause11(Suppl.6), 749–765 (2004).
12.
Recent review of randomized, controlled trials of hormonal therapies for the treatment of female sexual dysfunction.
13.
SherwinBB: The impact of different doses of oestrogen and oestrogen-androgens on mood and sexual behavior in postmenopausal women. J. Clin. Endocrin. Metab. 72(2), 336–343 (1991).
14.
WiklundIKarlbergJMattssonL: Quality of life of postmenopausal women on a regimen of transdermal estadiol therapy: a double-blind placebo-controlled study. Am. J. Obstet. Gynecol. 168(3), 824–830 (1993).
15.
HaysJOckeneJKBrunnerRL: Effects of oestrogen plus progestin on health related quality of life. N. Engl. J. Med. 348(10), 1839–1854 (2003).
16.
Nathorst-BoosJWiklundIMattssonLA: Is sexual life influenced by transdermal oestrogen therapy? A double-blind placebo-controlled study. Acta Obstet. Gynecol. Scand. 72, 656–660 (1993).
17.
DennersteinLBurrowsGDWoodC: Hormones and sexuality: effects of oestrogen and progestogen. Obstet. Gynecol. 56, 316–322 (1980).
18.
BusterJEKingsbergSAAguirreO: Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet. Gynecol. 105, 944–952 (2005).
19.
SherwinBBGelfandM: Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom. Med. 47(4), 339–351 (1985).
20.
ShifrenJLBraunsteinGDSimonJA: Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343(10), 682–688 (2000).
21.
FloterANathorst-BoosKCarlstromK: Addition of testosterone to oestrogen replacement in oophorectomized women: effects on sexuality and well being. Climacteric5, 357–365 (2002).
22.
MyersLSDixenJMorrissetteDCarmichaelMDavidsonJM: Effects of oestrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J. Clin. Endocrin. Metab. 70(4), 1124–1131 (1990).
23.
LoboRA: Comparative effects of oral esterified oestrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive desire disorder. Fertil Steril. 79, 1341–1352 (2003).
24.
DavisSRMcCloudPStraussBJBurgerH: Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas21, 227–236 (1995).
25.
BaulieuEEThomasGLegrainS: Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc. Natl Acad. Sci. USA97(8), 4279–4284 (2000).
26.
HackbertLHeimanJR: Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. J. Womens Health Gend. Based Med. 11(2), 155–162 (2002).
27.
MestonCMHeimanJR: Acute dehydroepiandrosterone effects on sexual arousal in premenopausal women. J. Sex Marital Ther. 28(1), 53–60 (2002).
28.
BarnhartKTFreemanEGrissoJA: The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J. Clin. Endocrinal Metab. 84, 3896–3902 (1999).
29.
Nathorst-BoosJHammarM: Effect on sexual life – a comparison between tibolone and a continuous estradiol-northisterone acetate regimen. Maturitas26, 15–20 (1997).
30.
LaanEvan LunsenRHEveraerdW: The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric4, 28–41 (2001).
31.
PalaciosSMenendezCJuradoARCastanoRVargasJC: Changes in sex behavior after menopause: effects of tibolone. Maturitas22, 155–161 (1995).
32.
EgarterCHuberJLeikermoserR: Tibolone versus conjugated oestrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas23, 55–62 (1996).
33.
KokcuACetinkayaMBYanikFAlperTMalatyaliogluE: The comparison of effects of tibolone and conjugated oestrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas36, 75–80 (2000).
34.
Castelo-BrancoCVicenteJJFiguerasF: Comparitive effects of oestrogen plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas36, 161–168 (2000).
35.
SiwekJGourlayMSlawsonDCShaughnessyAF: How to write an evidence-based clinical review article. Am. Fam. Physician65, 251–258 (2001).
36.
DavisSRTranJ: Testosterone influences libido and well being in women. Trends Endocrinol. Metab. 12, 33–37 (2001).
GeistSH: Androgen therapy in gynecology. JAMA117, 2207–2213 (1940).
39.
GreenblattRB: Evaluation of an androgen, oestrogen, oestrogen-androgen combination, and a placebo in the treatment of menopause. J. Clin. Endocrinol. Metab. 10(12), 1547–1558 (1950).
40.
BolourSYBraunsteinG: Testosterone therapy in women: a review. Int. J. Impot. Res. (2005) (In press).
41.
Recent review of testosterone therapy for the treatment of female sexual dysfunction.
42.
DimitrakakisCJonesRALiuABondyCA: Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause11, 531–535 (2004).
43.
SomboonpornWDavisSR: Testosterone effects on breast: implications for testosterone therapy for women. Endocr. Rev. 25, 374–388 (2004).
44.
ArltWCalliesFvan VlijmenJC: Dehydroepiandrosterone replacement in women with adrenal insufficiencyN. Engl. J. Med. 341, 1013–1020 (1999).
45.
HuntPJGurnellEMHuppertFA: Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's Disease in a randomized double-blind trial. J. Clin. Endocrinol. Metab. 85(12), 4650–4656 (2000).
46.
LovasKGebre-MedhimGTrovikTS: Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J. Clin. Endocrinal Metab. 88(3), 1112–1118 (2003).
47.
ModelskaKCummingsS: Tibolone for postmenopausal women: systematic review of randomized trials. J. Clin. Endocrinal Metab. 87(1), 16–23 (2002).
48.
Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet362, 419–427 (2003).
49.
LaeTFBassonRRosenRGiulianoFKhourySMontorsiF: Sexual Medicine: Sexual Dysfunction in Men and Women. Health Publications, Paris, France (2004).
50.
DavisSR: The effects of tibolone on mood and libido. Menopause9(3), 162–170 (2002).
51.
BermanJRBermanLATolerSMGillJHaughieS: Safety and efficacy of sildenafil for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled study. J. Urol. 170, 2333–2338 (2003).
52.
BassonRMcInnesRSmithMD: Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J. Womens Health Gend. Based Med. 11, 367–377 (2002).
53.
LandenMErikssonEAgrenHFahlenT: Effects of buspirone on sexual dysfunction in depressed patients treated with selective serotonin re-uptake inhibitors. J. Clin. Psychopharmacol. 19, 268–271 (1999).
54.
ClaytonAHWarnockJKKornsteinSGPinkertonRSheldon-KellerAMcgarveyEL: A placebo-controlled trial of buproprion SR as an antidote for selective-serotonin re-uptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry65(1), 62–67 (2004).
55.
SegravesRTClaytonACroftHWolfAWarnockJ: Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J. Clin. Psychopharmacol. 24(3), 339–342 (2004).
56.
ModellJGMayRSKatholiCR: Effects of buproprion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study. J. Sex Marital Ther. 26, 231–240 (2000).
57.
GardnerEA: Long-term preventitve care in depression: the use of buproprion in patients intolerant of other antidepressants. J. Clin. Psychiat. 44, 157–162 (1983).
58.
MasandPSAshtonAKGuptaSFrankB: Sustained-release bupropion for selective serotonin re-uptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. Am. J. Psychiat. 158(5), 805–807 (2001).
59.
CarusoSAgnelloCIntelisanoGFarinaMDi MariLCianciA: Placebo-controlled study on efficacy and safety of daily apomorphine sublingual intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology63(5), 955–959 (2004).
60.
MichelsonDBancroftJTargumSYongmanKTepnerR: Female sexual dysfunction with antidepressant administration: a randomized placebo-controlled study of pharmacologic intervention. Am. J. Psychiatry157(2), 239–243 (2000).
61.
RowlandDLTaiW: A review of plant-derived and herbal approaches to the treatment of sexual dysfunction. J. Sex. Marital Ther. 29(3), 185–205 (2003).
62.
LaGowB: PDR for Herbal Medicines, (3rd edition). Thomson PDR Publishers, Montvale, NJ, USA (2004).
63.
AschenbrennerDS: Avlimil taken for female sexual dysfunction. Am. J. Nurs. 104(10), 27–29 (2004).
64.
FergusonDMSteidleCPSinghGS: Randomized, placebo-controlled, double-blind, crossover design trial of the efficacy and safety of Zestra for women in women with and without female sexual arousal disorder. J. Sex. Marital Ther. 29, 33–44 (2003).
65.
ItoTTrantASPolanML: A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J. Sex Marital Ther. 27, 541–549 (2001).
66.
LauBHLauEW: Kyo-Green improves sexual dysfunction in men and women. Med. Sci. Monit. 9(2), PI12–PI18 (2003).
67.
EllisonJMDeLucaP: Fluoxetine-induced genital anesthesia relieved by Ginkgo biloba extract. J. Clin. Psychiat. 59, 199–200 (1998).
68.
AshtonAKAhrensKGuptaSMasandPS: Antidepressant-induced sexual dysfunction and Ginkgo biloba. Am. J. Psychiatry157, 836–837 (2000).
69.
KangBJLeeSJKimMDChoMJ: A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum. Psychopharmacol. 17(6), 279–284 (2002).
70.
CohenAJBartlikB: Ginkgo biloba for antidepressant-induced sexual dysfunction. J. Sex Marital Ther. 24, 139–143 (1998).
71.
JacobsenFM: Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J. Clin. Psychiatry53(4), 119–122 (1992).
72.
US Food and Drug Administrationwww.fda.gov (Accessed August 2005).
